INS and type 2 diabetes mellitus: The costs/QALY yielded by the analyses presented here indicate that liraglutide 1.8 mg added to basal insulin is a cost-effective treatment compared with lixisenatide 20 μg added to basal insulin in patients with T2D uncontrolled with basal insulin in Sweden.